Aeterna jumps on Macrilen approval

Aeterna Zentaris Inc. (TSX:AEZS; NASDAQ:AEZS) shares climbed Thursday after FDA approved a resubmitted NDA for Macrilen macimorelin acetate for use in diagnosing adult growth hormone deficiency (AGHD).

Aeterna added C$0.91 (35%) to C$3.48 in Toronto, and US$0.69 (34%) to US$2.70 on NASDAQ...